



- (51) International Patent Classification:
C12Q 1/00 (2006.01) *C07F 9/24* (2006.01)
- (21) International Application Number:
PCT/US2015/011677
- (22) International Filing Date:
16 January 2015 (16.01.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/928,147 16 January 2014 (16.01.2014) US
- (71) Applicants: **SONY CORPORATION** [JP/JP]; 1-7-1 Konan, Minato-ku, Tokyo, Japan 108-0075 (JP). **SONY CORPORATION OF AMERICA** [US/US]; 550 Madison Avenue, New York, New York 10022 (US).
- (72) Inventors: **MATRAY, Tracy**; 15233 78th Avenue Southeast, Snohomish, Washington 98296 (US). **HESHAM, Sherif**; 17112 Northeast 43rd Terrace, Redmond, Washington 98052 (US).
- (74) Agents: **HARWOOD, Eric, A.** et al.; Seed Intellectual Property Law Group PLLC, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE





FIG. 1

(57) Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): Formula (I), including stereoisomers, salts and tautomers thereof, wherein R^{1a} , R^{1b} , R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are as defined herein. Methods associated with preparation and use of such compounds are also provided.



(I)

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WATER SOLUBLE FLUORESCENT OR COLORED DYES
AND METHODS FOR THEIR USE

BACKGROUND OF THE INVENTION

Field of the Invention

5 The present invention is directed to novel fluorescent or colored dyes and methods for their preparation and use in various analytical methods.

Description of the Related Art

 There is a continuous and expanding need for rapid, highly specific methods of detecting and quantifying chemical, biochemical and biological substances as analytes in research and diagnostic mixtures. Of particular value are methods for
10 measuring small quantities of nucleic acids, peptides, saccharides, pharmaceuticals, metabolites, microorganisms, ions, and other materials of diagnostic value. Examples of such materials include narcotics and poisons, drugs administered for therapeutic purposes, hormones, pathogenic microorganisms and viruses, peptides, *e.g.*, antibodies
15 and enzymes, and nucleic acids, particularly those implicated in disease states.

 The presence of a particular analyte can often be determined by binding methods that exploit the high degree of specificity that characterizes many biochemical and biological systems. Frequently used methods are based on, for example, antigen-antibody systems, nucleic acid hybridization techniques, and protein-ligand systems. In
20 these methods, the existence of a complex of diagnostic value is typically indicated by the presence or absence of an observable "label" which is attached to one or more of the interacting materials. The specific labeling method chosen often dictates the usefulness and versatility of a particular system for detecting an analyte of interest. Preferred labels are inexpensive, safe, and capable of being attached efficiently to a wide variety
25 of chemical, biochemical, and biological materials without significantly altering the important binding affinities of those materials. The label should give a highly characteristic signal, and should be rarely, and preferably never, found in nature. The

label should be stable and detectable in aqueous systems over periods of time ranging up to months. Detection of the label is preferably rapid, sensitive, and reproducible without the need for expensive, specialized facilities or the need for special precautions to protect personnel. Quantification of the label is preferably relatively independent of
5 variables such as temperature and the composition of the mixture to be assayed.

A wide variety of labels have been developed, each with particular advantages and disadvantages. For example, radioactive labels are quite versatile, and can be detected at very low concentrations. However, such labels are expensive, hazardous, and their use requires sophisticated equipment and trained personnel. Thus,
10 there is wide interest in non-radioactive labels, particularly in labels that are observable by spectrophotometric, spin resonance, and luminescence techniques, and reactive materials, such as enzymes that produce such molecules.

Labels that are detectable using fluorescence spectroscopy are of particular interest because of the large number of such labels that are known in the art.
15 Moreover, the literature is replete with syntheses of fluorescent labels that are derivatized to allow their attachment to other molecules, and many such fluorescent labels are commercially available.

Cyanine dyes have been widely used for labeling biomolecules including antibodies, DNA probes, avidin, streptavidin, lipids, biochemical analogs, peptides, and
20 drugs, as well as for a variety of applications including DNA sequencing, DNA microarray, western blotting, flow cytometry analysis, and protein microarrays, to name a few. Scientists favor using cyanine dyes in biological applications because, among other reasons, cyanine dyes 1) are biocompatible; 2) have high molar absorptivity (c.a. $10^5 \text{ M}^{-1} \text{ cm}^{-1}$); 3) are readily modified to match a wide range of desired excitation and
25 detection wavelengths (*e.g.*, about 500 to about 900 nm); 4) are capable of incorporating water-soluble groups and linking groups; 5) and possess favorable fluorescence properties. In particular, Cy2 conjugates, with a maximum adsorption/excitation around 492 nm and emission around 510 nm, in the green region of the visible spectrum, are commonly used as an alternative to FITC due to reduced
30 sensitivity to pH changes. However, the low fluorescence quantum yield, short


fluorescence lifetime, propensity to photobleach, and poor chemical stability of Cy2 has limited its use in chemical and life sciences.

There is thus a need in the art for water soluble dyes and biomarkers that permit visual or fluorescent detection of biomolecules without prior illumination or chemical or enzymatic activation. Ideally, such dyes and biomarkers should be intensely colored or fluorescent and should be available in a variety of colors and fluorescent wavelengths. The present invention fulfills this need and provides further related advantages.

BRIEF SUMMARY OF THE INVENTION


In brief, the present invention is generally directed to compounds useful as water soluble, fluorescent or colored dyes and probes that enable visual detection of biomolecules and other analytes, as well as reagents for their preparation. Methods for visually detecting a biomolecule and for determining the size of a biomolecule are also described. The water soluble, fluorescent or colored dyes of the invention are intensely colored and/or fluorescent and can be readily observed by visual inspection or other means. In some embodiments the compounds may be observed without prior illumination or chemical or enzymatic activation. Advantageously, embodiments of the dyes have a maximum absorbance ranging from about 468 nm to about 508 nm and a maximum emission ranging from about 495 nm to about 525 nm. For example, in certain embodiment the dyes have a maximum absorbance at about 490 nm and a maximum emission at about 505 nm. The dyes are thus ideal for use in various analytical methods. By appropriate selection of the dye, as described herein, visually detectable biomolecules of a variety of colors may be obtained.

Accordingly, in one embodiment a compound having the following structure (I) is provided:



or a salt, stereoisomer or tautomer thereof, wherein R^{1a} , R^{1b} , R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are as defined herein.

5 In other embodiments, an analyte molecule comprising a covalent bond to a compound having the following structure (I'):



10 or a salt, stereoisomer or tautomer thereof is provided, wherein R^{1a} , R^{1b} , R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are as defined herein and wherein at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is the analyte molecule or a linkage thereto.

15 In another embodiment, a method for staining a sample is provided; the method comprises adding to said sample a representative compound as described herein in an amount sufficient to produce an optical response when said sample is illuminated at an appropriate wavelength.

In still other embodiments, the present disclosure provides a method for visually detecting a biomolecule, comprising:

- (a) providing a representative compound described herein; and
- (b) detecting the compound by its visible properties.

5 Other disclosed methods include a method for visually detecting a biomolecule, the method comprising:

- (a) admixing any of the disclosed compounds with one or more biomolecules; and
- (b) detecting the compound by its visible properties.

10 Other embodiments are directed to a composition comprising any one of the disclosed compounds and one or more biomolecules. Use of such composition in analytical methods for detection of the one or more biomolecules is also provided.

These and other aspects of the invention will be apparent upon reference to the following detailed description.

15 DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the ^1H NMR spectrum of compound 2 in CDCl_3 .

FIG. 2 depicts a representative total diode array chromatogram (215-500nm) of a $2\mu\text{L}$ injection volume of compound 2. System used was a Waters Acquity UHPLC system with a $2.1\text{mm} \times 50\text{mm}$ Acquity BEH-C18 column held at 45°C .

20 FIG. 3 depicts the background-subtracted mass spectrum of brominated anthracene derivative 2 product. Expected mass: 617.8.

FIG. 4 depicts the ^1H NMR spectrum of compound 3 in CDCl_3 .

FIG. 5 depicts a representative total diode array chromatogram (215-500nm) of a $2\mu\text{L}$ injection volume of compound 3. System used was a Waters Acquity
25 UHPLC system with a $2.1\text{mm} \times 50\text{mm}$ Acquity BEH-C18 column held at 45°C .

FIG. 6 depicts the background-subtracted mass spectrum of compound 3. Expected mass 929.1.

FIG. 7 depicts a representative chromatogram at 488nm of a $10\mu\text{L}$ injection volume of compound 5 (crude 5'-NH₃-(HEG)-AQ6-(HEG)-3' sequence).

System used was a Waters Acquity UHPLC system with a 2.1mm x 50mm Acquity BEH-C18 column held at 45°C.

FIG. 8 depicts the background-subtracted mass spectrum of compound 5 (crude 5'-NH₃-(HEG)-AQ6-(HEG)-3' sequence). The method employs electrospray ionization in negative mode and shows ⁻1, ⁻2, and ⁻3 charge states.

DETAILED DESCRIPTION OF THE INVENTION

In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the invention. However, one skilled in the art will understand that the invention may be practiced without these details.

Unless the context requires otherwise, throughout the present specification and claims, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to”.

Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

“Amino” refers to the -NH₂ group.

“Carboxy” refers to the -CO₂H group.

“Cyano” refers to the -CN group.

“Formyl” refers to the -C(=O)H group.

“Hydroxy” or “hydroxyl” refers to the -OH group.

“Imino” refers to the =NH group.

“Nitro” refers to the -NO₂ group.

“Oxo” refers to the =O substituent group.

“Sulfhydryl” refers to the –SH group.

“Thioxo” refers to the =S group.

“Alkyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated (*i.e.*,
5 contains one or more double and/or triple bonds), having from one to twelve carbon atoms (C₁-C₁₂ alkyl), preferably one to eight carbon atoms (C₁-C₈ alkyl) or one to six carbon atoms (C₁-C₆ alkyl), and which is attached to the rest of the molecule by a single bond, *e.g.*, methyl, ethyl, *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, *n*-pentyl,
10 1,1-dimethylethyl (*t*-butyl), 3-methylhexyl, 2-methylhexyl, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted.

“Alkylene” or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a substituent group, consisting
15 solely of carbon and hydrogen, which is saturated or unsaturated (*i.e.*, contains one or more double and/or triple bonds), and having from one to twelve carbon atoms, *e.g.*, methylene, ethylene, propylene, *n*-butylene, ethenylene, propenylene, *n*-butenylene, propynylene, *n*-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single or double bond and to the substituent group through a
20 single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the substituent group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted.

“Alkoxy” refers to a group of the formula -OR_a where R_a is an alkyl
25 group as defined above containing one to twelve carbon atoms. A “hydroxylalkoxy” is an alkoxy moiety comprising at least one hydroxyl substituent. An “aminoalkoxy” is an alkoxy moiety comprising at least one amino substituent. Unless stated otherwise specifically in the specification, alkoxy, hydroxylalkoxy and/or aminoalkoxy groups are optionally substituted.

“Alkylamino” refers to a group of the formula $-NHR_a$ or $-NR_aR_a$ where each R_a is, independently, an alkyl group as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group is optionally substituted.

5 “Alkylether” refers to any alkyl group as defined above, wherein at least one carbon-carbon bond is replaced with a carbon-oxygen bond. The carbon-oxygen bond may be on the terminal end (as in an alkoxy group) or the carbon oxygen bond may be internal (*i.e.*, C-O-C). Alkylethers include at least one carbon oxygen bond, but may include more than one (*i.e.*, a “polyalkylether”). For example, polyethylene glycol
10 (PEG), which is a polyalkylether, is included within the meaning of alkylether. “Hydroxypolyalkylether” refers to a polyalkylether comprising one or more hydroxyl substituents. “Aminopolyalkylether” refers to a polyalkylether comprising one or more amino substituents. Unless stated otherwise specifically in the specification, an alkylether, polyalkylether, hydroxypolyalkylether and/or aminopolyalkylether group is
15 optionally substituted.

“Alkyleneether” refers to any alkylene group as defined above, wherein at least one carbon-carbon bond is replaced with a carbon-oxygen bond. The carbon-oxygen bond may be on the terminal end (as in an alkoxy group) or the carbon oxygen bond may be internal (*i.e.*, C-O-C). Alkyleneethers include at least one carbon oxygen
20 bond, but may include more than one. For example, polyethylene glycol (PEG) is included within the meaning of alkyleneether. Unless stated otherwise specifically in the specification, an alkyleneether group is optionally substituted.

“Alkylphospho” refers to the $-RP(=O)(R_a)R_b$ group, wherein R is an alkylene group, R_a is OH, O^- or OR_c ; and R_b is $-Oalkyl$ or $-Oalkylether$, wherein R_c is a
25 counter ion (*e.g.*, Na^+ and the like). Unless stated otherwise specifically in the specification, an alkylphospho group may be optionally substituted. For example, in certain embodiments, the alkyl or alkylether moiety (R_b) in an alkylphospho group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or
30 thiophosphoalkylether, which substituents are also optionally substituted.

“Oalkylphospho” is an alkylphospho group connected to the remainder of the molecule via an oxygen atom. Unless stated otherwise specifically in the specification, an Oalkylphospho group is optionally substituted. For example, in certain embodiments, the alkyl, alkylether or polyalkylether moiety (R_b) in an Oalkylphospho group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are also optionally substituted.

“Alkyetherphospho” refers to the $-RP(=O)(R_a)R_b$ group, wherein R is an alkylene ether group, R_a is OH, O^- or OR_c ; and R_b is $-Oalkyl$ or $-Oalkylether$, wherein R_c is a counter ion (e.g., Na^+ and the like). Unless stated otherwise specifically in the specification, an alkyletherphospho group is optionally substituted. For example, in certain embodiments, the alkyl or alkylether moiety (R_b) in an alkyletherphospho group is optionally substituted with one or more of hydroxyl, amino sulfhydryl or a phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are also optionally substituted.

“Oalkyletherphospho” is an alkyletherphospho group connected to the remainder of the molecule via an oxygen atom. Unless stated otherwise specifically in the specification, an Oalkyletherphospho group is optionally substituted. For example, in certain embodiments, the alkyl or alkylether moiety (R_b) in an Oalkyletherphospho group is optionally substituted with one or more of hydroxyl, amino sulfhydryl or a phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are also optionally substituted.

“Alkylthiophospho” refers to the $-RP(=R_a)(R_b)R_c$ group, wherein R is an alkylene group, R_a is O or S, R_b is OH, O^- , S^- , OR_d or SR_d ; and R_c is $-Oalkyl$ or $-Oalkylether$, wherein R_d is a counter ion (e.g., Na^+ and the like) and provided that: R_a is S or R_b is S^- or SR_d ; or provided that R_a is S and R_b is S^- or SR_d . Unless stated otherwise specifically in the specification, an alkylthiophospho group is optionally substituted. For example, in certain embodiments, the alkyl or alkylether moiety in an alkylthiophospho group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl,

phosphoalkylether or thiophosphoalkylether, which substituents are also optionally substituted.

“Oalkylthiophospho” is an alkylthiophospho group connected to the remainder of the molecule via an oxygen atom. Unless stated otherwise specifically in the specification, an Oalkylthiophospho group is optionally substituted. For example, in certain embodiments, the alkyl or alkylether moiety in an Oalkylthiophospho group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are also optionally substituted.

“Alkyletherthiophospho” refers to the $-RP(=R_a)(R_b)R_c$ group, wherein R is an alkylenether group, R_a is O or S, R_b is OH, O^- , S^- , OR_d or SR_d ; and R_c is -Oalkyl or -Oalkylether, wherein R_d is a counter ion (*e.g.*, Na^+ and the like) and provided that: R_a is S or R_b is S^- or SR_d ; or provided that R_a is S and R_b is S^- or SR_d . Unless stated otherwise specifically in the specification, an alkyletherthiophospho group is optionally substituted. For example, in certain embodiments, the alkyl or alkylether moiety in a alkyletherthiophospho group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are also optionally substituted.

“Oalkyletherthiophospho” is an alkyletherthiophospho group connected to the remainder of the molecule via an oxygen atom. Unless stated otherwise specifically in the specification, an Oalkyletherthiophospho group may be optionally substituted. For example, in certain embodiments, the alkyl or alkylether moiety in an Oalkyletherthiophospho group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are also optionally substituted.

“Amidyl” refers to the $-NR_aR_b$ radical, wherein R_a and R_b are independently H, alkyl or aryl. Unless stated otherwise specifically in the specification, an amide group is optionally substituted.

“Aryl” refers to a hydrocarbon ring system group comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. For purposes of this invention, the aryl group may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Aryl groups include, but are not limited to, 5 aryl groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, *as*-indacene, *s*-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the term “aryl” or the prefix “ar-“ (such as in “aralkyl”) is meant to include aryl groups that are 10 optionally substituted.

“Aryloxy” refers to a group of the formula $-OR_a$, where R_a is an aryl moiety as defined above, for example phenoxy and the like. Unless stated otherwise specifically in the specification, an aryloxy group is optionally substituted.

“Aralkyl” refers to a group of the formula $-R_b-R_c$ where R_b is an alkylene 15 chain as defined above and R_c is one or more aryl groups as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group is optionally substituted.

“Oaralkyl” is an aralkyl group which is connected to the remainder of the molecule via an oxygen linkage. “ODMT” refers to dimethoxytrityl linked to the 20 rest of the molecule via an O atom. Unless stated otherwise specifically in the specification, an Oaralkyl group is optionally substituted.

“Cyanoalkyl” refers to an alkyl group comprising at least one cyano substituent. The one or more $-CN$ substituents may be on a primary, secondary or tertiary carbon atom. Unless stated otherwise specifically in the specification, a 25 cyanoalkyl group is optionally substituted.

“Cycloalkyl” or “carbocyclic ring” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated 30 or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic

cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl groups include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group is
5 optionally substituted.

“Cycloalkylalkyl” refers to a group of the formula $-R_bR_d$ where R_b is an alkylene chain as defined above and R_d is a cycloalkyl group as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group is optionally substituted.

10 “Multicyclic” refers to any molecule having more than one ring. The rings may be either, fused, spirocyclic or separated by one or more atoms (*e.g.*, linked via an acyclic linker).

“Spirocyclic” refers to a multicyclic molecule wherein two rings share a single carbon atom.

15 “Fused” refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.

20 “Halo” or “halogen” refers to bromo, chloro, fluoro or iodo.

“Haloalkyl” refers to an alkyl group, as defined above, that is substituted by one or more halo groups, as defined above, *e.g.*, trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification,
25 a haloalkyl group is optionally substituted.

“Heterocyclyl” or “heterocyclic ring” refers to a stable 3- to 18-membered non-aromatic ring group which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl
30 group may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may

include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl group may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl group may be partially or fully saturated. Examples of such heterocyclyl groups include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolanyl, imidazolidinyl, 5 isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 10 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, a heterocyclyl group is optionally substituted.

“*N*-heterocyclyl” refers to a heterocyclyl group as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl group to the rest of the molecule is through a nitrogen atom in the heterocyclyl group. 15 Unless stated otherwise specifically in the specification, a *N*-heterocyclyl group is optionally substituted.

“Heterocyclylalkyl” refers to a group of the formula $-R_bR_e$ where R_b is an alkylene chain as defined above and R_e is a heterocyclyl group as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be 20 attached to the alkyl group at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group is optionally substituted.

“Heteroaryl” refers to a 5- to 14-membered ring system group comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one 25 aromatic ring. For purposes of this invention, the heteroaryl group may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl group may be optionally oxidized; the nitrogen atom may be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, 30 benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl,

benzothiazolyl, benzothiadiazolyl, benzo[*b*][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-*a*]pyridinyl, carbazolyl, cinnolinyl, 5 dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indoliny, isoindoliny, isoquinolyl, indoliziny, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1*H*-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, 10 pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazoliny, quinoxaliny, quinoliny, quinuclidiny, isoquinoliny, tetrahydroquinoliny, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (*i.e.*, thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group is optionally substituted.

15 “*N*-heteroaryl” refers to a heteroaryl group as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl group to the rest of the molecule is through a nitrogen atom in the heteroaryl group. Unless stated otherwise specifically in the specification, an *N*-heteroaryl group is optionally substituted.

20 “Heteroarylalkyl” refers to a group of the formula -R_bR_f where R_b is an alkylene chain as defined above and R_f is a heteroaryl group as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group is optionally substituted.

25 “Hydroxylalkyl” refers to an alkyl group comprising at least one hydroxyl substituent. The one or more -OH substituents may be on a primary, secondary or tertiary carbon atom. Unless stated otherwise specifically in the specification, hydroxyalkyl group is optionally substituted.

 “Hydroxylalkylether” refers to an alkylether group comprising at least one hydroxyl substituent. The one or more -OH substituents may be on a primary,

secondary or tertiary carbon atom. Unless stated otherwise specifically in the specification, hydroxyalkylether group is optionally substituted.

“Phosphate” refers to the $-OP(=O)(R_a)R_b$ group, wherein R_a is OH, O^- or OR_c ; and R_b is OH, O^- , OR_c , a further phosphate group (as in diphosphate and triphosphate) thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, wherein R_c is a counter ion (*e.g.*, Na^+ and the like). Unless stated otherwise specifically in the specification, a phosphate group is optionally substituted.

“Phospho” refers to the $-P(=O)(R_a)R_b$ group, wherein R_a is OH, O^- or OR_c ; and R_b is OH, O^- , OR_c , a phosphate group (as in diphosphate and triphosphate) thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, wherein R_c is a counter ion (*e.g.*, Na^+ and the like). Unless stated otherwise specifically in the specification, a phospho group is optionally substituted.

“Phosphoalkyl” refers to the $-P(=O)(R_a)R_b$ group, wherein R_a is OH, O^- or OR_c ; and R_b is -Oalkyl, wherein R_c is a counter ion (*e.g.*, Na^+ and the like). Unless stated otherwise specifically in the specification, a phosphoalkyl group is optionally substituted. For example, in certain embodiments, the alkyl moiety in a phosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl or a phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituent is optionally substituted.

“Ophosphoalkyl” is a phosphoalkyl group connected to the remainder of the molecule via an oxygen atom. Unless stated otherwise specifically in the specification, an Ophosphoalkyl group is optionally substituted. For example, in certain embodiments, the alkyl moiety in an Ophosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl or a phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituent is optionally substituted.

“Phosphoalkylether” refers to the $-P(=O)(R_a)R_b$ group, wherein R_a is OH, O^- or OR_c ; and R_b is -Oalkylether (including poly ethers such as

polyethyleneoxide ethers and the like), wherein R_c is a counter ion (*e.g.*, Na^+ and the like). Unless stated otherwise specifically in the specification, a phosphoalkylether group is optionally substituted. For example, in certain embodiments, the alkylether moiety in a phosphoalkylether group is optionally substituted with one or more of
5 hydroxyl, amino, sulfhydryl, phosphate, phospho, thiophospho, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are optionally substituted.

“Ophosphoalkylether” is a phosphoalkylether group connected to the remainder of the molecule via an oxygen atom. Unless stated otherwise specifically in
10 the specification, an ophosphoalkylether group is optionally substituted. For example, in certain embodiments, the alkylether moiety in an Ophosphoalkylether group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, phospho, thiophospho, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are optionally
15 substituted.

“Phosphoramidite” refers to the $-OP(OR^a)(NR^b)_2$ group, wherein R^a is alkyl and each R^b is independently H or alkyl. Unless stated otherwise specifically in the specification, a phosphoramidite group is optionally substituted.

“Activated phosphorous” refers to any moiety comprising phosphorous
20 which is cable of reaction with a nucleophile, for example reacting with a nucleophile at the phosphorous atom. For example, phosphoramidites and moieties comprising P-halogen bonds are included within the definition of activated phosphorous moieties. Unless stated otherwise specifically in the specification, an activated phosphorous group is optionally substituted.

25 “Protected hydroxyl” refers to a hydroxyl moiety wherein the H has been reversibly replaced with a protecting group. Protecting groups are well known in the art. In certain embodiments, a protected hydroxyl will be an ether (*e.g.*, alkoxy, arylalkoxy or aryloxy). A non-limiting example of a protected hydroxyl is dimethoxytrityl ether. Other protected hydroxyl moieties are well-known in the art.

Unless stated otherwise specifically in the specification, a protected hydroxyl group is optionally substituted.

“Sulphydrylalkyl” refers to an alkyl group comprising at least one sulphydryl substituent. The one or more –SH substituents may be on a primary,
5 secondary or tertiary carbon atom. Unless stated otherwise specifically in the specification, a sulphydrylalkyl group is optionally substituted.

“Sulphydrylalkylether” refers to an alkylether group comprising at least one sulphydryl substituent. The one or more –SH substituents may be on a primary,
secondary or tertiary carbon atom. Unless stated otherwise specifically in the
10 specification, a sulphydrylalkylether group is optionally substituted.

“Sulfonate” refers to the $-\text{OS}(\text{O})_2\text{R}_a$ group, wherein R_a is alkyl or aryl. Unless stated otherwise specifically in the specification, a sulfonate group is optionally substituted.

“Thioalkyl” refers to a group of the formula $-\text{SR}_a$ where R_a is an alkyl
15 group as defined above containing from one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group is optionally substituted.

“Thiophosphate” refers to the $-\text{OP}(=\text{R}_a)(\text{R}_b)\text{R}_c$ group, wherein R_a is O or S, R_b is OH, O^- , S^- , OR_d or SR_d ; and R_c is OH, O^- , OR_d , a phosphate group, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or
20 thiophosphoalkylether, wherein R_d is a counter ion (*e.g.*, Na^+ and the like) and provided that: R_a is S or R_b is S^- or SR_d ; or provided that R_a is S and R_b is S^- or SR_d . Unless stated otherwise specifically in the specification, a thiophosphate group is optionally substituted.

“Thiophospho” refers to the $-\text{P}(=\text{R}_a)(\text{R}_b)\text{R}_c$ group, wherein R_a is O or S,
25 R_b is OH, O^- , S^- , OR_d or SR_d ; and R_c is OH, O^- , OR_d , a phosphate group, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, wherein R_d is a counter ion (*e.g.*, Na^+ and the like) and provided that: R_a is S or R_b is S^- or SR_d ; or provided that R_a is S and R_b is S^- or SR_d . Unless stated otherwise specifically in the specification, a thiophospho group is optionally substituted.

“Thiophosphoalkyl” refers to the $-P(=R_a)(R_b)R_c$ group, wherein R_a is O or S, R_b is OH, O^- , S^- , OR_d or SR_d ; and R_c is -Oalkyl, wherein R_d is a counter ion (*e.g.*, Na^+ and the like) and provided that: R_a is S or R_b is S^- or SR_d ; or provided that R_a is S and R_b is S^- or SR_d . Unless stated otherwise specifically in the specification, a thiophosphoalkyl group is optionally substituted. For example, in certain embodiments, the alkyl moiety in a thiophosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are optionally substituted.

10 “Othiophosphoalkyl” is a thiophosphoalkyl group connected to the remainder of the molecule via an oxygen atom. Unless stated otherwise specifically in the specification, an Othiophosphoalkyl group is optionally substituted. For example, in certain embodiments, the alkyl moiety in an Othiophosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, 15 phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are optionally substituted.

“Thiophosphoalkylether” refers to the $-P(=R_a)(R_b)R_c$ group, wherein R_a is O or S, R_b is OH, O^- , S^- , OR_d or SR_d ; and R_c is -Oalkylether, wherein R_d is a counter ion (*e.g.*, Na^+ and the like) and provided that: R_a is S or R_b is S^- or SR_d ; or provided that 20 R_a is S and R_b is S^- or SR_d . Unless stated otherwise specifically in the specification, a thiophosphoalkylether group is optionally substituted. For example, in certain embodiments, the alkylether moiety in a thiophosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, phospho, thiophospho, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or 25 thiophosphoalkylether, which substituents are optionally substituted.

“Othiophosphoalkylether” is a thiophosphoalkylether group connected to the remainder of the molecule via an oxygen atom. Unless stated otherwise specifically in the specification, an Othiophosphoalkylether group is optionally substituted. For example, in certain embodiments, the alkylether moiety in an Othiophosphoalkyl group 30 is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate,

phospho, thiophospho, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, which substituents are optionally substituted.

The term “substituted” used herein means any of the above groups (*e.g.*,
 5 alkyl, alkylene, alkoxy, alkylamino, alkylether, polyalkylether, hydroxylpolyalkylether, aminopolyalkylether, alkylenether, alkylphospho, alkyletherphospho, alkylthiophospho, alkyletherthiophospho, amidyl, thioalkyl, aryl, aryloxy, aralkyl, Oaralkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, *N*-heterocyclyl, heterocyclylalkyl, heteroaryl, *N*-heteroaryl, heteroarylalkyl, hydroxylalkyl, aminoalkyl,
 10 hydroxylalkylether, phospho, phosphoalkyl, phosphoalkylether, phosphoramidite, activated phosphorous, protected hydroxyl, sulfhydrylalkyl, sulfhydrylalkylether, sulfonate, thioalkyl, thiophospho, thiophosphoalkyl and/or thiophosphoalkylether) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups
 15 such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, *N*-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkylarylsilyl
 20 groups, and triarylsilyl groups; and other heteroatoms in various other groups. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (*e.g.*, a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted”
 25 includes any of the above groups in which one or more hydrogen atoms are replaced with $-NR_gR_h$, $-NR_gC(=O)R_h$, $-NR_gC(=O)NR_gR_h$, $-NR_gC(=O)OR_h$, $-NR_gSO_2R_h$, $-OC(=O)NR_gR_h$, $-OR_g$, $-SR_g$, $-SOR_g$, $-SO_2R_g$, $-OSO_2R_g$, $-SO_2OR_g$, $=NSO_2R_g$, and $-SO_2NR_gR_h$. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with $-C(=O)R_g$, $-C(=O)OR_g$, $-C(=O)NR_gR_h$, $-CH_2SO_2R_g$,
 30 $-CH_2SO_2NR_gR_h$. In the foregoing, R_g and R_h are the same or different and

independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, *N*-heterocyclyl, heterocyclylalkyl, heteroaryl, *N*-heteroaryl and/or heteroarylalkyl. "Substituted" further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, *N*-heterocyclyl, heterocyclylalkyl, heteroaryl, *N*-heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.

10 "Fluorescent" refers to a molecule which is capable of absorbing light of a particular frequency and emitting light of a different frequency. Fluorescence is well-known to those of ordinary skill in the art.

"Colored" refers to a molecule which absorbs light within the colored spectrum (*i.e.*, red, yellow, blue and the like).

15 A "linker" refers to a contiguous chain of at least one atom, such as carbon, oxygen, nitrogen, sulfur, phosphorous and combinations thereof, which connects a portion of a molecule to another portion of the same molecule or to a different molecule, moiety or solid support (*e.g.*, microparticle). Linkers may connect the molecule via a covalent bond or other means, such as ionic or hydrogen bond interactions.

20 For purposes of the present invention, the term "biomolecule" refers to any of a variety of biological materials, including nucleic acids, carbohydrates, amino acids, polypeptides, glycoproteins, hormones, aptamers and mixtures thereof. More specifically, the term is intended to include, without limitation, RNA, DNA, oligonucleotides, modified or derivatized nucleotides, enzymes, receptors, prions, receptor ligands (including hormones), antibodies, antigens, and toxins, as well as bacteria, viruses, blood cells, and tissue cells. The visually detectable biomolecules of the invention (*i.e.*, compounds of structure (I) having a biomolecule linked thereto) are prepared, as further described herein, by contacting a biomolecule with a compound having a reactive group that enables attachment of the biomolecule to the compound via

any available atom or functional group, such as an amino, hydroxy, carboxyl, or sulfhydryl group on the biomolecule.

The terms "visible" and "visually detectable" are used herein to refer to substances that are observable by visual inspection, without prior illumination, or
5 chemical or enzymatic activation. Such visually detectable substances absorb and emit light in a region of the spectrum ranging from about 300 to about 900 nm. Preferably, such substances are intensely colored, preferably having a molar extinction coefficient of at least about 40,000, more preferably at least about 50,000, still more preferably at least about 60,000, yet still more preferably at least about 70,000, and most preferably
10 at least about 80,000 $M^{-1}cm^{-1}$. The biomolecules of the invention may be detected by observation with the naked eye, or with the aid of an optically based detection device, including, without limitation, absorption spectrophotometers, transmission light microscopes, digital cameras and scanners. Visually detectable substances are not limited to those which emit and/or absorb light in the visible spectrum. Substances
15 which emit and/or absorb light in the ultraviolet (UV) region (about 10 nm to about 400 nm), infrared (IR) region (about 700 nm to about 1 mm), and substances emitting and/or absorbing in other regions of the electromagnetic spectrum are also included with the scope of "visually detectable" substances.

For purposes of the invention, the term "photostable visible dye" refers
20 to a chemical moiety that is visually detectable, as defined hereinabove, and is not significantly altered or decomposed upon exposure to light. Preferably, the photostable visible dye does not exhibit significant bleaching or decomposition after being exposed to light for at least one hour. More preferably, the visible dye is stable after exposure to light for at least 12 hours, still more preferably at least 24 hours, still yet more
25 preferably at least one week, and most preferably at least one month. Nonlimiting examples of photostable visible dyes suitable for use in the compounds and methods of the invention include azo dyes, thioindigo dyes, quinacridone pigments, dioxazine, phthalocyanine, perinone, diketopyrrolopyrrole, quinophthalone, and truarycarbonium.

The visually detectable biomolecules of the invention are useful for a
30 wide variety of biochemical and biomedical applications in which there is a need to

determine the presence, location, or quantity of a particular biomolecule. In another aspect, therefore, the invention provides a method for visually detecting a biomolecule, comprising: (a) providing a biological system with a visually detectable biomolecule comprising the compound of structure (I) linked to a biomolecule; and (b) detecting the biomolecule by its visible properties. For purposes of the invention, the phrase "detecting the biomolecule by its visible properties" means that the biomolecule, without illumination or chemical or enzymatic activation, is observed with the naked eye, or with the aid of an optically based detection device, including, without limitation, absorption spectrophotometers, transmission light microscopes, digital cameras and scanners. A densitometer may be used to quantify the amount of visually detectable biomolecule present. For example, the relative quantity of the biomolecule in two samples can be determined by measuring relative optical density. If the stoichiometry of dye molecules per biomolecule is known, and the extinction coefficient of the dye molecule is known, then the absolute concentration of the biomolecule can also be determined from a measurement of optical density. As used herein, the term "biological system" is used to refer to any solution or mixture comprising one or more biomolecules in addition to the visually detectable biomolecule. Nonlimiting examples of such biological systems include cells, cell extracts, tissue samples, electrophoretic gels, assay mixtures, and hybridization reaction mixtures.

20 "Microparticle" refers to any of a number of small particles useful for attachment to compounds of the invention, including, but not limited to, glass beads, magnetic beads, polymeric beads, nonpolymeric beads, and the like. In certain embodiments, a microparticle comprises polystyrene, such as polystyrene beads.

Embodiments of the invention disclosed herein are also meant to encompass all compounds of structure (I) being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , ^{123}I , and ^{125}I , respectively.

Isotopically-labeled compounds of structure (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described below and in the following Examples using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

5 “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

 “Optional” or “optionally” means that the subsequently described event or circumstances may or may not occur, and that the description includes instances
10 where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl group may or may not be substituted and that the description includes both substituted alkyl groups and alkyl groups having no substitution.

 “Salt” includes both acid and base addition salts.

15 “Acid addition salt” refers to those salts which are formed with inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid,
20 camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid,
25 hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid,

sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, *p*-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.

“Base addition salt” refers to those salts which are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from
5 inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine,
10 trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine,
15 *N*-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

Often crystallizations produce a solvate of the compound of the invention. The present invention includes all solvates of the described compounds. As
20 used herein, the term “solvate” refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate,
25 trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. The compounds of the invention may be true solvates, while in other cases the compounds of the invention may merely retain adventitious water or another solvent or be a mixture of water plus some adventitious solvent.

The compounds of the invention, or their salts, tautomers or solvates
30 may contain one or more asymmetric centers and may thus give rise to enantiomers,


diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (*R*)- or (*S*)- or, as (*D*)- or (*L*)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (*R*)- and (*S*)-, or (*D*)- and (*L*)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both *E* and *Z* geometric isomers. Likewise, all tautomeric forms are also intended to be included.

A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another.

A “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any said compounds. Various tautomeric forms of the compounds are easily derivable by those of ordinary skill in the art.

The chemical naming protocol and structure diagrams used herein are a modified form of the I.U.P.A.C. nomenclature system, using the ACD/Name Version 9.07 software program and/or ChemDraw Ultra Version 11.0 software naming program (CambridgeSoft). Common names familiar to one of ordinary skill in the art are also used.

As noted above, in one embodiment of the present invention, compounds useful as fluorescent and/or colored dyes in various analytical methods are provided. The compounds have the following structure (I):





or a salt, stereoisomer or tautomer thereof, wherein:

- 5 R^{1a} and R^{1b} are each independently hydroxyl or alkoxy; and
 R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} ,
 R^{2q} , R^{2r} and R^{2s} are each independently H, halo or $-L^1-R^3$;


10 R^3 is, at each occurrence, independently an analyte molecule or alkyl substituted with one or more of hydroxyl, protected hydroxyl, amino, alkylamino, alkoxy, polyalkylether, hydroxylalkoxy, aminoalkoxy, hydroxylpolyalkylether, aminopolyalkylether, phosphate, thiophosphate, phospho, thiophospho, phosphoalkylether, Ophosphoalkylether thiophosphoalkylether, Othiophosphoalkylether, phosphoramidite or activated phosphorous; or R^3 is a microparticle; and


L^1 is an optional linker moiety.

- 15 In some other embodiments, the compound has one of the following structures (Ia) or (Ib):




5 In more embodiments, the compound has one of the following structures (Ic) or (Id):






In still other embodiments, the compound has one of the following structures (Ie) or (If):



5

or



In some specific embodiments of the above, the compound has structure (If).

In various embodiments, R^{1a} or R^{1b} is hydroxyl. In other embodiments, R^{1a} or R^{1b} is alkoxy. For example, in some embodiments each of R^{1a} and R^{1b} are alkoxy.

In some of the foregoing embodiments, alkoxy is C_1 - C_6 alkoxy, such as methoxy.

In some of any of the foregoing embodiments, at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is H.

In other of the foregoing embodiments, at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is halo. In some more specific embodiments, at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} or R^{2h} is halo, for example in some embodiments R^{2b} is halo. In some of any of the foregoing embodiments, halo is bromo.

In various other embodiments, at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is $-L^1-R^3$. For example, in some embodiments at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} or R^{2h} is $-L^1-R^3$. In more specific embodiments, R^{2b} is $-L^1-R^3$.

In still other embodiments, R^{2b} is $-L^1-R^3$ and R^{2a} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are H.

In some embodiments, R^3 is, at each occurrence, independently an analyte molecule or alkyl substituted with one or more of hydroxyl, protected hydroxyl, amino, alkylamino, alkoxy, polyalkylether, hydroxylalkoxy, aminoalkoxy, hydroxylpolyalkylether, aminopolyalkylether, phosphate, thiophosphate, phospho, thiophospho, phosphoalkylether, thiophosphoalkylether, phosphoramidite or activated phosphorous; or R^3 is a microparticle. In some of the foregoing embodiments, the phosphoalkylether is an Ophosphoalkylether. In other of the foregoing embodiments, the thiophosphoalkylether is an Othiophosphoalkylether.

In some of the foregoing embodiments, R^3 is, at each occurrence, independently alkyl substituted with one or more of hydroxyl, protected hydroxyl,

amino, alkylamino, alkoxy, polyalkylether, hydroxylalkoxy, aminoalkoxy, hydroxylpolyalkylether, aminopolyalkylether, phosphate, thiophosphate, phospho, thiophospho, phosphoalkylether, thiophosphoalkylether, phosphoramidite or activated phosphorous. For example, in some embodiments R^3 is alkyl substituted with one or
5 more substituents selected from hydroxyl, amino, trityl ether, phosphoramidite, phospho, phosphoalkylether, phosphate and polyethylene glycol.

In some of the foregoing embodiments, R^3 is, at each occurrence, independently alkyl substituted with one or more of hydroxyl, protected hydroxyl, amino, alkylamino, alkoxy, polyalkylether, hydroxylalkoxy, aminoalkoxy,
10 hydroxylpolyalkylether, aminopolyalkylether, phosphate, thiophosphate, phospho, thiophospho, phosphoalkylether, Ophosphoalkylether, thiophosphoalkylether, Othiophosphoalkylether, phosphoramidite or activated phosphorous. For example, in some embodiments R^3 is alkyl substituted with one or more substituents selected from hydroxyl, amino, trityl ether, phosphoramidite, phospho, phosphoalkylether,
15 Ophosphoalkylether, phosphate and polyethylene glycol.

In some embodiments, R^3 is, at each occurrence, independently alkyl substituted with one or more Ophosphoalkylether.


For example, in some embodiments of the above, R^3 is, at each occurrence, independently alkyl substituted with one or more phosphoalkylether groups,
20 such as Ophosphoalkylether groups, and the alkyl ether of the polyalkylether is a polyalkylether such as ethylene glycol. In some of these embodiments the alkylether of the phosphoalkylether is substituted with a substituent selected from hydroxyl and a further phosphoalkylether moiety, such as a further Ophosphoalkylether moiety, which may be substituted with hydroxyl and/or amino.

25 In other embodiments, R^3 is, at each occurrence, independently alkyl substituted with two Ophosphoalkylether groups. In some of these embodiments, the alkylether moiety is a polyalkylether, such as a polyethylene oxide. In some other of these embodiments, the alkylether moieties are substituted with one or more substituents selected from hydroxyl, amino and a further a further Ophosphoalkylether moiety, and

the alkylether of the further Ophosphoalkyether moiety is optionally substituted with hydroxyl and/or amino.

It is understood that some embodiments of the compound of structure (I) comprise two or more R³ groups. In such embodiments, the R³ groups may be the same or different. In certain embodiments, the compound of structure (I) comprises a single R³ moiety. i.e., only one of R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{2e}, R^{2f}, R^{2g}, R^{2h}, R²ⁱ, R^{2j}, R^{2k}, R^{2l}, R^{2m}, R²ⁿ, R^{2o}, R^{2p}, R^{2q}, R^{2r} or R^{2s} is -L¹-R³.

In various other embodiments of any of the foregoing, R³ has one of the following structures:



15 wherein:

n¹, n² and n³ are each independently an integer from 1 to 6; and
 x and y are each independently an integer from 1 to 10.

In some of the above embodiments, n^1 , n^2 and n^3 are each 1. In other embodiments, L^1 is absent and R^3 connects directly to the remainder of the compound of structure (I).

In some other embodiments of the above, x is 5. In other embodiments,
5 y is 5. In some more embodiments x and y are each 5.

In some different embodiments, R^3 is an analyte molecule, such as a biomolecule. In certain embodiments R^3 is a biomolecule selected from nucleic acids, amino acids and polymers thereof (*e.g.*, DNA, oligonucleotides, proteins, polypeptides, and the like).


10 In still other embodiments, R^3 is a biomolecule, and the biomolecule is a nucleic acid, peptide, carbohydrate, lipid, enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer, antigen or prion.

In some different embodiments, R^3 is an analyte molecule selected from a drug, vitamin and small molecule.

15 In some of the foregoing embodiments, the linker L^1 is present. When present, L^1 is conveniently selected to provide a covalent attachment between R^3 and the remainder of the compound of structure (I). Exemplary L^1 moieties include, but are not limited to, O, N, S, P and alkylene bonds, and combinations thereof. Suitable L^1 groups are derivable by one of ordinary skill in the art.

20 In other embodiments, L^1 is absent.


In some embodiments where L^1 is present, L^1 comprises a phosphate bond to the analyte molecule. In some of these embodiments, L^1 has the following structure:





25 wherein n^1 , n^2 and n^3 are each independently an integer from 1 to 6. In various other embodiments, n^1 , n^2 and n^3 are each 1.


The structure of the compound of structure (I) is selected to optimize the absorbance and or emission wavelengths. Accordingly, in various embodiments the compound of structure (I) has a maximum absorbance ranging from about 468 nm to about 508 nm, for example from about 478 nm to about 498 nm. In other embodiments, the compound of structure (I) has a maximum emission ranging from about 495 nm to about 525 nm, for example, from about 495 to about 515 nm. For example, in certain embodiment the dyes have a maximum absorbance at about 490 nm and a maximum emission at about 505 nm.

In some more specific embodiments, the compound of structure (I) has one of the following structures:




(1)






(4)




(5)



wherein R³ is an analyte molecule.

In various other embodiments, the invention provides an analyte molecule comprising a covalent bond to a compound having the following structure (I'):



or a salt thereof, wherein:

- R^{1a} and R^{1b} are each independently hydroxyl or alkoxy; and
- R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{2e}, R^{2f}, R^{2g}, R^{2h}, R²ⁱ, R^{2j}, R^{2k}, R^{2l}, R^{2m}, R²ⁿ, R^{2o}, R^{2p}, R^{2q}, R^{2r} and R^{2s} are each independently H, halo or -L¹-R³;

R^3 is the analyte molecule; and

L^1 is an optional linker moiety,

wherein at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is $-L^1-R^3$.

5 The analyte molecule may be selected from any appropriate analyte molecules, including the analyte molecules described herein above.

 Compositions comprising any of the foregoing compounds and one or more biomolecules are provided in various other embodiments. In some embodiments, use of such compositions in analytical methods for detection of the one or more
10 biomolecules is also provided as described in more detail below.

 It is understood that any embodiment of the compounds of structure (I), as set forth above, and any specific choice set forth herein for a R^{1a} , R^{1b} , R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} , R^{2s} , L^1 or R^3 variable in the compounds of structure (I), as set forth above, may be independently
15 combined with other embodiments and/or variables of the compounds of structure (I) to form embodiments of the inventions not specifically set forth above. In addition, in the event that a list of choices is listed for any particular R or L group in a particular embodiment and/or claim, it is understood that each individual choice may be deleted from the particular embodiment and/or claim and that the remaining list of choices will
20 be considered to be within the scope of the invention.


 It is understood that in the present description, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds.

 It will also be appreciated by those skilled in the art that in the process
25 described herein the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Suitable protecting groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for
30 amino, amidino and guanidino include *t*-butoxycarbonyl, benzyloxycarbonyl, and the

like. Suitable protecting groups for mercapto include -C(O)-R'' (where R'' is alkyl, aryl or arylalkyl), *p*-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, *Protective Groups in Organic Synthesis* (1999), 3rd Ed., Wiley. As one of skill in the art would appreciate, the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.

Furthermore, all compounds of the invention which exist in free base or acid form can be converted to their salts by treatment with the appropriate inorganic or organic base or acid by methods known to one skilled in the art. Salts of the compounds of the invention can be converted to their free base or acid form by standard techniques.

The following Reaction Scheme illustrates exemplary methods of making compounds of this invention, *i.e.*, compound of structure (I):




wherein R^{1a}, R^{1b}, R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{2e}, R^{2f}, R^{2g}, R^{2h}, R²ⁱ, R^{2j}, R^{2k}, R^{2l}, R^{2m}, R²ⁿ, R^{2o}, R^{2p}, R^{2q}, R^{2r}, R^{2s}, R³ and L¹ are as defined above.

It is understood that one skilled in the art may be able to make these compounds by similar methods or by combining other methods known to one skilled in the art. It is also understood that one skilled in the art would be able to make, in a similar manner as described below, other compounds of structure (I) not specifically

illustrated below by using the appropriate starting components and modifying the parameters of the synthesis as needed. In general, starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art (see, for example, *Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 5th edition (Wiley, December 2000)) or prepared as described in this invention.

Reaction Scheme I



10 Reaction Scheme I illustrates an exemplary method for preparing compounds of structure I. Referring to Reaction Scheme 1, compounds of structure **A** and **B** can be purchased or prepared by methods well-known to those of ordinary skill in the art. Treatment of 2 equivalents of **A** with a strong base, such as n-butyl lithium, followed by reaction with **B** results in compounds of structure (I). Although Reaction

Scheme I depicts preparation of symmetrical (*i.e.*, identical naphthyl groups) compounds of structure (I), it will be readily apparent to one of ordinary skill in the art that other, non-symmetrical, compounds of structure (I) can be prepared by similar methods (*e.g.*, stepwise reaction of differently substituted naphthyls).

5 Further, compounds of structure (I) obtained by the above methods can be further modified to obtain different compounds of structure (I). For example, in certain embodiments the compounds of structure (I) comprise at least one $-L^1-R^3$ moiety. In such embodiments, the $-L^1-R^3$ moiety, or precursor thereof, may be installed via any well-known method, such as Suzuki coupling. Analyte molecules
10 (*e.g.*, biomolecules) can be attached via an optional L^1 linker by any one of many common methods. For example, modification of the above scheme to include reactive groups capable of forming covalent bonds with a functional group on an analyte molecule is one means for attaching analyte molecules. Reactive groups include, but are not limited to activated phosphorus compounds (*e.g.*, phosphoramidites), activated
15 esters, amines, alcohols, and the like. Methods for preparation of such compounds and reacting the same with an analyte molecule to form a covalent bond are well-known in the art.

In some embodiments, the compounds of structure (I) comprise a covalent bond to an oligonucleotide. Such bonds may be formed by including a
20 phosphoramidite moiety in the compound of structure (I) and reacting the same with an oligomer (or phosphoramidite monomer) under standard DNA synthesis conditions. DNA synthesis methods are well-known in the art. Briefly, two alcohol groups are functionalized with a dimethoxytrityl (DMT) group and a 2-cyanoethyl-N,N-diisopropylamino phosphoramidite group, respectively. The phosphoramidite group is
25 coupled to an alcohol group, typically in the presence of an activator such as tetrazole, followed by oxidation of the phosphorous atom with iodine. The dimethoxytrityl group can be removed with acid (*e.g.*, chloroacetic acid) to expose the free alcohol, which can be reacted with a phosphoramidite group. The 2-cyanoethyl group can be removed after oligomerization by treatment with aqueous ammonia.

Preparation of the phosphoramidites used in the oligomerization methods is also well-known in the art. For example, a primary alcohol can be protected as a DMT group by reaction with DMT-Cl. A secondary alcohol is then functionalized as a phosphoramidite by reaction with an appropriate reagent such as 2-cyanoethyl N,N-dissopropylchlorophosphoramidite. Methods for preparation of phosphoramidites and their oligomerization are well-known in the art and described in more detail in the examples.

In still other embodiments, the compounds are useful in various analytical methods. For example, in certain embodiments the disclosure provides a method of staining a sample, the method comprising adding to said sample a compound of structure (I) in an amount sufficient to produce an optical response when said sample is illuminated at an appropriate wavelength.

In yet other embodiments of the foregoing method, one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is $-L^1-R^3$ where R^3 is an analyte molecule such as a biomolecule. For example, in some embodiments the biomolecule is nucleic acid, amino acid or a polymer thereof (*e.g.*, polynucleotide or polypeptide). In still more embodiments, the biomolecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.

In yet other embodiments of the foregoing method, one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is $-L^1-R^3$ where R^3 is a microparticle. For example, in some embodiments the microparticle is a polymeric bead or nonpolymeric bead.

In even more embodiments, said optical response is a fluorescent response.

In other embodiments, said sample comprises cells, and some embodiments further comprise observing said cells by flow cytometry.

In still more embodiments, the method further comprises distinguishing the fluorescence response from that of a second fluorophore having detectably different optical properties.

In other embodiments, the disclosure provides a method for visually detecting a biomolecule, comprising:

(a) providing a compound of structure (I), wherein one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is $-L^1-R^3$
5 where R^3 is a biomolecule; and

(b) detecting the compound by its visible properties.

For example, in some embodiments the biomolecule is a nucleic acid, amino acid or a polymer thereof (*e.g.*, polynucleotide or polypeptide). In still more
10 embodiments, the biomolecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.

In other embodiments, a method for visually detecting a biomolecule is provided, the method comprising:

(a) admixing any of the foregoing compounds with one or more biomolecules; and

15 (b) detecting the compound by its visible properties.

As noted above, certain embodiments of the compounds of structure (I) comprise an analyte molecule (*e.g.*, biomolecule) or a ligand attached (conjugated) thereto. Attachment may be, for example, by covalent bonding, ionic bonding, dative bonding, hydrogen bonding, and other forms of molecular bonding.

20 Several types of analyte molecules are suitable for conjugation to the compounds of structure (I). For example, useful conjugated substrates of the invention include, but are not limited to, compounds of structure (I) comprising an analyte molecule attached thereto (also referred to herein as a “conjugated substrate”), the analyte molecule being selected from antigens, small molecules, steroids, vitamins,
25 drugs, haptens, metabolites, toxins, environmental pollutants, amino acids, peptides, proteins, photosensitizers, nucleotides, oligonucleotides, nucleic acids, carbohydrates, lipids, ion-complexing moieties and non-biological polymers. In one exemplary embodiment, the conjugated substrate is a natural or synthetic amino acid, a natural or synthetic peptide or protein, or an ion-complexing moiety. Exemplary peptides include,
30 but are not limited to protease substrates, protein kinase substrates, phosphatase

substrates, neuropeptides, cytokines, and toxins. Exemplary protein conjugates include enzymes, antibodies, lectins, glycoproteins, histones, alumin, lipoproteins, avidin, streptavidins, protein A, protein G, casein, phycobiliproteins, other fluorescent proteins, hormones, toxins, growth factors, and the like.

5 The point of attachment of the analyte molecule to the remainder of the compound of structure (I) can and will vary depending upon the embodiment. Further, some embodiments include a linker (L^1) between the analyte molecule and the remainder of the compound of structure (I), although use of the linker is optional and not required in all embodiments. It is also envisioned that the compound of structure (I)
10 may comprise more than one analyte molecule. For example, two, three or more than three analyte molecules may be conjugated to the naphthyl and/or anthracene rings of compound (I).

Several methods of linking dyes to various types of analyte molecules are well known in the art. For example, methods for conjugating dyes to an analyte
15 molecule are described in R. Haugland, *The Handbook: A Guide to Fluorescent Probes and Labeling Technologies*, 9th Ed., 2002, Molecular Probes, Inc., and the references cited therein; and Brindley, 1992, *Bioconjugate Chem.* 3:2, which are all incorporated herein by reference. By way of example, a compound of the disclosure may include a
20 covalent bond to DNA or RNA via one or more purine or pyrimidine bases through an amide, ester, ether, or thioether bond; or is attached to the phosphate or carbohydrate by a bond that is an ester, thioester, amide, ether, or thioether. Alternatively, a compound of structure (I) may be bound to the nucleic acid by chemical post-modification, such as with platinum reagents, or using a photoactivatable molecule such as a conjugated psoralen.

25 xThe compounds of the invention are useful in many applications including those described for other dyes in U.S. Pat. Nos. 7,172,907; 5,268,486; and U.S. Patent Application Nos. 20040014981; and 20070042398, all of which are incorporated herein by reference in their entireties. For example, fluorescent dyes, such as those described herein, may be used in imaging with techniques such as those based
30 on fluorescence detection, including but not limited to fluorescence lifetime, anisotropy,

photoinduced electron transfer, photobleaching recovery, and non-radioactive transfer. The compounds of structure (I), as such, may be utilized in all fluorescent-based imaging, microscopy, and spectroscopy techniques including variations on such. In addition, they may also be used for photodynamic therapy and in multimodal imaging.

5 Exemplary fluorescence detection techniques include those that involve detecting fluorescence generated within a system. Such techniques include, but are not limited to, fluorescence microscopy, fluorescence activated cell sorting (FACS), fluorescent flow cytometry, fluorescence correlation spectroscopy (FCS), fluorescence in situ hybridization (FISH), multiphoton imaging, diffuse optical tomography, molecular

10 imaging in cells and tissue, fluorescence imaging with one nanometer accuracy (FIONA), free radical initiated peptide sequencing (FRIPs), and second harmonic retinal imaging of membrane potential (SHRIMP), as well as other methods known in the art.

Alternatively, the compounds of structure (I) can be used as markers or

15 tags to track dynamic behavior in living cells. In this regard, fluorescence recovery after photobleaching (FRAP) can be employed in combination with the subject compounds to selectively destroy fluorescent molecules within a region of interest with a high-intensity laser, followed by monitoring the recovery of new fluorescent molecules into the bleached area over a period of time with low-intensity laser light.


20 Variants of FRAP include, but are not limited to, polarizing FRAP (pFRAP), fluorescence loss in photo-bleaching (FLIP), and fluorescence localization after photobleaching (FLAP). The resulting information from FRAP and variants of FRAP can be used to determine kinetic properties, including the diffusion coefficient, mobile fraction, and transport rate of the fluorescently labeled molecules. Methods for such

25 photo-bleaching based techniques are described in Braeckmans, K. et al., *Biophysical Journal* 85: 2240-2252, 2003; Braga, J. et al., *Molecular Biology of the Cell* 15: 4749-4760, 2004; Haraguchi, T., *Cell Structure and Function* 27: 333-334, 2002; Gordon, G. W. et al., *Biophysical Journal* 68: 766-778, 1995, which are all incorporated herein by reference in their entireties.

Other fluorescence imaging techniques are based on non-radioactive energy transfer reactions that are homogeneous luminescence assays of energy transfer between a donor and an acceptor. Such techniques that may employ the use of the subject fluorescent dyes include, but are not limited to, FRET, FET, FP, HTRF, BRET, 5 FLIM, FLI, TR-FRET, FLIE, smFRET, and SHREK. These techniques are all variations of FRET.

The subject compounds may be used as biosensors such as a Ca^{2+} ion indicator; a pH indicator; a phosphorylation indicator, or an indicator of other ions, e.g., magnesium, sodium, potassium, chloride and halides. For example, biochemical 10 processes frequently involve protonation and deprotonation of biomolecules with concomitant changes in the pH of the milieu. Substitution at the meso-position with different pH-sensitive groups generates a variety of NIR fluorescent pH sensors with different pKa's. To be effective, the substituents at the meso-position will be in extended π -conjugation with the fluorophore core to effect marked spectral changes in 15 response to different pH environments.

Uses of the disclosed compounds are in no way limited to analytical methods. In various embodiments, the compounds are used as colorants or dyes in various applications. In this respect, the substituents on the core anthracene and/or naphthalene moieties are not particularly limited provided the compound maintains its 20 desired color and/or absorbance and/or emission properties. Selection of appropriate substituents for this purpose is within the skill of one of ordinary skill in the art. Accordingly, in some embodiments a compound useful as a dye or colorant is provided having the following structure (I'')



or a salt thereof, wherein R^{1a} , R^{1b} , R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are each independently H or a substituent, the substituent being selected based on the desired color and or emission/absorbance properties of the compound.

In certain embodiments of the compound of structure (I'') R^{1a} and R^{1b} are each independently hydroxyl or alkoxy; and R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are each independently H, halo or alkyl.

In some embodiments the compounds disclosed herein (*e.g.*, (I), (I') and/or (I'')) find utility as a dye or colorant in textiles, plastics, paints and/or safety devices (*e.g.*, reflective materials, emergency lights, glow sticks, etc.) One of ordinary skill in the art will readily recognize other uses for the disclosed compounds.

The following examples are provided for purposes of illustration, not limitation.

EXAMPLES

General Methods


^1H NMR spectra were obtained on a JEOL 400 MHz spectrometer. ^1H spectra were referenced against TMS. Reverse phase HPLC dye analysis was performed using a Waters Acquity UHPLC system with a 2.1mm x 50mm Acquity BEH-C18 column held at 45°C. Mass spectral analysis was performed on a Waters/Micromass Quattro micro MS/MS system (in MS only mode) using MassLynx

4.1 acquisition software. Mobile phase used for LC/MS on dyes was 100 mM 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), 8.6 mM triethylamine (TEA), pH 8. Phosphoramidites and precursor molecules were analyzed using an Agilent Infinity 1260 UHPLC system with a diode array detector and High Performance Autosampler
5 using an Aapptec© Spirit™ Peptide C18 column (4.6mm x 100mm, 5µm particle size). Molecular weights for monomer intermediates were obtained using tropylium cation infusion enhanced ionization. Excitation and emission profiles experiments were recorded on a Cary Eclipse spectra photometer.

All reactions were carried out in oven dried glassware under a nitrogen
10 atmosphere unless otherwise stated. Commercially available DNA synthesis reagents were purchased from Glen Research (Sterling, VA). Anhydrous pyridine, toluene, dichloromethane, diisopropylethyl amine, triethylamine, acetic acid, pyridine, and THF were purchased from Aldrich. All other chemicals were purchased from Aldrich or TCI and were used as is with no additional purification.

15

EXAMPLE 1

SYNTHESIS OF 2-BROMO-9,10-BIS((6-METHOXYNAPHTHALEN-1-
YL)ETHYNYL)ANTHRACENE (1)

(1)

20


A clean, dry 200 mL round bottom flask was flushed with nitrogen and dry THF (40 mL). 1-ethynyl-6-methoxynaphthalene (2.0g, 10.9 mmol) was added and

the flask which was then cooled in an acetone dry ice bath under a nitrogen atmosphere for 30 minutes. Upon cooling, nBuLi 2.5M in hexanes (4.4 mL, 10.9 mmol) was added dropwise, and the reaction was allowed to stir for 1hr. 2-Bromoanthraquinone (1.05g, 3.6 mmol) and ether (30 mL) were added, after which the reaction was allowed to warm to room temperature and stirred overnight. A solution of 0.1 M SnCl₂ in 1M HCl (44 mL) was then added in one portion. After 2 hours, the reaction mixture was poured into methanol (200 mL), and the resulting slurry was stirred for one hour. The red solid was isolated by filtration and dried under vacuum (1.15g, 51%).

The ¹H NMR spectrum of compound 1 is depicted in Figure 1. The RP total diode array chromatogram at 215-500 nm of compound is depicted in Figure 2. The mass spectrum of compound 1 is depicted in Figure 3.

EXAMPLE 2

SYNTHESIS OF 3-(9,10-BIS((6-METHOXYNAPHTHALEN-1-YL)ETHYNYL)ANTHRACEN-2-YL)-2-((BIS(4-METHOXYPHENYL)(PHENYL)METHOXY)METHYL)PROPAN-1-OL (2)



(2)


15

A 250 mL round bottom flask fitted with a condenser was purged with nitrogen and dry THF (50 mL) followed by addition of 2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)prop-2-en-1-ol (2.2 g, 5.6 mmol). 9-BBN 0.5

M in THF (30.7 mL, 14.0 mmol) was added via syringe, and the reaction was heated to reflux for 12 hrs. After allowing the reaction to cool to room temperature, 3M K₂CO₃ (2.4 ml) and dry THF (150 mL) were added. Compound 1 (1.74 g, 2.8 mmol) and PdCl₂(dppf) (0.41g, 0.56 mmol) were added, and the solution was refluxed for 6 hrs and
5 allowed to cool to room temperature over two hours. The reaction mixture was poured into CH₂Cl₂ (300 mL) and washed with H₂O (300 mL). The aqueous layer was back extracted with additional CH₂Cl₂ (100 mL). The combined organic layers were washed with sat. NaCl (300 mL), dried over Na₂SO₄, and concentrated in vacuo to a viscous gum. The isolated crude product wash then purified by silica gel column
10 chromatography eluting with a gradient of CH₂Cl₂:hexanes (100:0 v/v) – (0:100 v/v) give 3 as a red solid (1.0 g, 35%). The ¹H NMR spectrum of compound 2 is depicted in Figure 4. The total diode array chromatogram at 215-500 nm of compound 2 is depicted in Figure 5. The mass spectrum of compound 2 is depicted in Figure 6.

EXAMPLE 3

SYNTHESIS OF 3-(9,10-BIS((6-METHOXYNAPHTHALEN-1-YL)ETHYNYL)ANTHRACEN-2-YL)-2-((BIS(4-METHOXYPHENYL)(PHENYL)METHOXY)METHYL)PROPYL 2-CYANOETHYL DIISOPROPYLPHOSPHORAMIDITE (3)



5

A dry 100 mL round bottom flask was purged with nitrogen, followed by addition of CH_2Cl_2 (20 mL) and compound 3 (0.20g, 0.21 mmol). N,N-Diisopropylethylamine (0.18 mL, 10.7 mmol) and 2-cyanoethyl diisopropylchlorophosphoramidite (0.15 mL, 0.6 mmol) were added via syringe. After 1 hour of stirring at room temperature, the reaction was determined to be complete by TLC analysis. The crude reaction mixture was then concentrated in vacuo to a dark gum. The residue was dissolved in acetonitrile and concentrated to dryness and used without further purification for dye assembly.

EXAMPLE 4

SYNTHESIS OF OLIGONUCLEOTIDE DYES

Compound 3 was used to prepare further dye compounds on an Applied Biosystems 394 DNA/RNA synthesizer on a 1 μ mol scale. The compounds comprised a 3'-phosphate group. Dyes were synthesized directly on CPG beads or on polystyrene solid support. The dyes were synthesized in the 3' to 5' direction by standard solid phase DNA methods. Coupling methods employed standard β -cyanoethyl phosphoramidite chemistry conditions. All phosphoramidite monomers were dissolved in acetonitrile/ dichloromethane (0.1 M solutions), and were added in successive order using the following synthesis cycles: 1) removal of the 5'-dimethoxytrityl protecting group with dichloroacetic acid in toluene, 2) coupling of the next phosphoramidite with activator reagent in acetonitrile, 3) oxidation with iodine/pyridine/water, and 4) capping with acetic anhydride/1-methylimidazole/acetonitrile. The synthesis cycle was repeated until the 5'-oligofloroside was assembled. At the end of the chain assembly, the monomethoxytrityl (MMT) group or dimthoxytrityl (DMT) group was removed with dichloroacetic acid in dichloromethane or dichloroacetic acid in toluene. The dyes were cleaved from the solid support using concentrated aqueous ammonium hydroxide at room temperature for 2-4 hours. The product was concentrated in vacuo and Sephadex G-25 columns were used to isolate the main product, which give RP-HPLC traces as shown in Figure 7 (compound 5). Figure 8 shows mass spectral data for dye prepared according to the above procedures (compound 5). Compound 4 was prepared according to the above general procedure by coupling compound 3 to the support followed by standard cleavage and deprotection.

Structures, spectral properties and molecular weights (MW) determined by electrospray mass spectrometry for exemplary compounds are presented in Table1.

Table 1. Representative intermediates and oligonucleotide dye sequences and their observed masses and optical properties.

Compound Name	Description	Calculated Mass	Observed Mass	λ_{max} , abs	λ_{max} , em
compound 4	5'-a6-3'	706.7	707.6	490	505
compound 5	5'-NH ₃ -(heg)-a6-(heg)-3'	1563.9	1564.3	490	505
compound 2	DMT-alcohol Intermediate	929.1	930.1; 1020.1 (mass + Tr)	488	508
compound 1	brominated Intermediate	617.5	618.2; 709.8 (mass + Tr)	488	508

Code	Desc.
a6	Anthracene core
NH ₃	5'Amino-5-modifier
(heg)	hexaethylene glycol spacer
DMT	4,4'-Dimethoxytrityl functional group
Tr	Tropylium cation

5

All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification, including U.S. provisional patent application Serial No. 61/928,147, filed January 16, 2014, are incorporated herein by reference, in their entireties to the extent not inconsistent with the present description.


10

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

What is claimed is:

1. A compound having the following structure (I):



or a salt, stereoisomer or tautomer thereof, wherein:


R^{1a} and R^{1b} are each independently hydroxyl or alkoxy; and

R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are each independently H, halo or $-L^1-R^3$;


R^3 is, at each occurrence, independently an analyte molecule or alkyl substituted with one or more of hydroxyl, protected hydroxyl, amino, alkylamino, alkoxy, polyalkylether, hydroxylalkoxy, aminoalkoxy, hydroxylpolyalkylether, aminopolyalkylether, phosphate, thiophosphate, phospho, thiophospho, phosphoalkylether, Ophosphoalkylether, thiophosphoalkylether, Othiophosphoalkylether, phosphoramidite or activated phosphorous; or R^3 is a microparticle; and

L^1 is an optional linker moiety.

2. The compound of claim 1, wherein the compound has one of the following structures (Ia) or (Ib):




(Ia)




(Ib)


3. The compound of claim 1, wherein the compound has one of the following structures (Ic) or (Id):




or



4 The compound of claim 1, wherein the compound has one of the following structures (Ie) or (If):



(Ie)



(If)

5. The compound of claim 4, wherein the compound has structure (If).


6. The compound of any one of the preceding claims, wherein R^{1a} or R^{1b} is hydroxyl.

7. The compound of any one of the preceding claims, wherein R^{1a} or R^{1b} is alkoxy.

8. The compound of any one of claims 1-5, wherein each of R^{1a} and R^{1b} are alkoxy.
9. The compound of any one of claims 7 or 8, wherein alkoxy is C_1 - C_6 alkoxy.
10. The compound of claim 9, wherein C_1 - C_6 alkoxy is methoxy.
11. The compound of any one of claims 1-10, wherein at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is H.
12. The compound of any one of claims 1-11, wherein at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is halo.
13. The compound of claim 12, wherein at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} or R^{2h} is halo
14. The compound of claim 13, wherein R^{2b} is halo.
15. The compound of any one of claims 12-14, wherein halo is bromo.
16. The compound of any one of claims 1-13, wherein at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is $-L^1-R^3$.
17. The compound of any one of claims 1-13, wherein at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} or R^{2h} is $-L^1-R^3$.

18. The compound of claim 17, wherein R^{2b} is $-L^1-R^3$.
19. The compound of claim 18, wherein R^{2a} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are H.
20. The compound of any one of claims 16-19, wherein R^3 is, at each occurrence, independently alkyl substituted with one or more of hydroxyl, protected hydroxyl, amino, alkylamino, alkoxy, polyalkyether, hydroxylalkoxy, aminoalkoxy, hydroxylpolyalkyether, aminopolyalkyether, phosphate, thiophosphate, phospho, thiophospho, phosphoalkylether, Ophosphoalkylether, thiophosphoalkylether, Othiophosphoalkylether, phosphoramidite or activated phosphorous.
21. The compound of claim 20, wherein R^3 is, at each occurrence, independently alkyl substituted with one or more substituents selected from hydroxyl, amino, trityl ether, phosphoramidite, phospho, phosphoalkylether, Ophosphoalkylether, phosphate and polyethylene glycol.
22. The compound of claim 20, wherein R^3 is, at each occurrence, independently alkyl substituted with one or more Ophosphoalkylether groups.

23. The compound of claim 21, wherein R³ has, at each occurrence, independently one of the following structures:



wherein:

n^1 , n^2 and n^3 are each independently an integer from 1 to 6; and
 x and y are each independently an integer from 1 to 10.

24. The compound of claim 23, wherein n^1 , n^2 and n^3 are each 1.

25. The compound of claim 23 or 24, wherein L¹ is absent.

26. The compound of any one of claims 16-19, wherein R³ is, at each occurrence, independently an analyte molecule.

27. The compound of claim 26, wherein the analyte molecule is a biomolecule.

28. The compound of claim 27, wherein the biomolecule is a nucleic acid, amino acid or a polymer thereof.


29. The compound of claim 27, wherein the biomolecule is a nucleic acid, peptide, carbohydrate, lipid, enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer, antigen or prion.

30. The compound of claim 27, wherein the analyte molecule is a drug, vitamin or small molecule.

31. The compound of any one of claims 22-30, wherein L^1 is present.

32. The compound of claim 31, wherein L^1 comprises a phosphate bond to the analyte molecule.


33. The compound of claim 32, wherein L^1 has the following structure:




wherein n^1 , n^2 and n^3 are each independently an integer from 1 to 6.

34. The compound of claim 33, wherein n^1 , n^2 and n^3 are each 1.


35. The compound of claim 1, wherein the compound has one of the following structures:




(1)




(2)




(3)



(4)



(5)




or

(6)

wherein R^3 is an analyte molecule.

36. An analyte molecule comprising a covalent bond to a compound having the following structure (I'):



or a salt thereof, wherein:

R^{1a} and R^{1b} are each independently hydroxyl or alkoxy; and
 R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} and R^{2s} are each independently H, halo or $-L^1-R^3$;
 R^3 is, at each occurrence, independently the analyte molecule; and
 L^1 is an optional linker moiety,
 wherein at least one of R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , R^{2h} , R^{2i} , R^{2j} , R^{2k} , R^{2l} , R^{2m} , R^{2n} , R^{2o} , R^{2p} , R^{2q} , R^{2r} or R^{2s} is $-L^1-R^3$.

37. A method of staining a sample, the method comprising adding to the sample the analyte molecule of claim 36 in an amount sufficient to produce an optical response when said sample is illuminated at an appropriate wavelength.

38. The method of claim 37, wherein said optical response is a fluorescent response.

39. The method of any one of claims 37-38, wherein said sample comprises cells.
40. The method of claim 39 further comprising observing said cells by flow cytometry.
41. The method of claim 40, further comprising distinguishing the fluorescence response from that of a second fluorophore having detectably different optical properties.
42. A method for visually detecting an analyte molecule, the method comprising:
- (a) providing the compound of claim 36; and
 - (b) detecting the compound by its visible properties.
43. A method for visually detecting a biomolecule, the method comprising:
- (a) admixing the compound of any of claims 1-36 with one or more biomolecules; and
 - (b) detecting the compound by its visible properties.
44. A composition comprising the compound of any one of claims 1-36 and one or more biomolecules.
45. Use of the composition of claim 44 in an analytical method for detection of the one or more biomolecules.

1/8



FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8